

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below, addressed to: Assistant Commissioner for Patents Washington, D.C. 20231, on December 19, 2000

LAW OFFICES OF JONATHAN ALAN QUINE

By Alexandra Allison  
Alexandra Allison

Attorney Docket No. 1012-102US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas William Rademacher, et al.

Application No.: Not yet known

Filed: Herewith

For: INOSITOLPHOSPHOGLYCAN AND  
RIBOSE FOR TREATMENT OF  
ISCHAEMIA-REPERFUSION INJURY

Examiner: Unassigned

Art Unit: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS

Please amend the claims to as follows, without prejudice to subsequent renewal of the specification in its original form. **Per the requirements of 37 C.F.R. § 1.121, the following claims are to be substituted for the corresponding previously pending claims of the same number(s). A marked up version showing the changes to the claims, is attached herewith. For the Examiner's convenience, a complete claim set of the currently pending claims is also submitted herewith.**

- Sub B1*
- a'*
- a2*
- a3*
- B*
- |     |  |
|-----|--|
| 4.  | (Amended). The composition of claim 1, further comprising adenosine or purine, or a nucleotide precursor thereof.                  |
| 7.  | (Amended). A composition of <u>claim 1</u> , for use in a method of medical treatment.   |
| 11. | (Amended). The use of <u>claim 8</u> , wherein the ischaemic-reperfusion injury arises from myocardial infarct, surgery or stroke. |